Esperite 주식 주식분석 | 주식가격 | 뉴스 | ESP.AS | NL0009272137 |

날짜	Esperite 주식 가격
	0.01 undefined
	0.01 undefined

날짜	Esperite 매출	Esperite EBIT	Esperite 이익
2017	16.55 백만 undefined	-7.29 백만 undefined	-12.72 백만 undefined
2016	26.25 백만 undefined	-5.46 백만 undefined	-8.41 백만 undefined
2015	27.52 백만 undefined	-7.55 백만 undefined	-7.06 백만 undefined
2014	27.61 백만 undefined	-3.45 백만 undefined	-5.01 백만 undefined
2013	29.81 백만 undefined	368,000 undefined	-3.51 백만 undefined
2012	36.84 백만 undefined	-1.27 백만 undefined	-17.1 백만 undefined
2011	41.85 백만 undefined	2.94 백만 undefined	2.32 백만 undefined
2010	40.4 백만 undefined	4.46 백만 undefined	2.55 백만 undefined
2009	38.39 백만 undefined	4.73 백만 undefined	1.35 백만 undefined
2008	29.49 백만 undefined	2.31 백만 undefined	2.57 백만 undefined
2007	17.71 백만 undefined	5.07 백만 undefined	3.88 백만 undefined
2006	10.92 백만 undefined	2.77 백만 undefined	2.04 백만 undefined
2005	8.67 백만 undefined	2.56 백만 undefined	2.35 백만 undefined
2004	6.36 백만 undefined	-260,000 undefined	-370,000 undefined

	매출	EBIT	이익
2004	6.36 백만 EUR	-260,000 EUR	-370,000 EUR
2005	8.67 백만 EUR	2.56 백만 EUR	2.35 백만 EUR
2006	10.92 백만 EUR	2.77 백만 EUR	2.04 백만 EUR
2007	17.71 백만 EUR	5.07 백만 EUR	3.88 백만 EUR
2008	29.49 백만 EUR	2.31 백만 EUR	2.57 백만 EUR
2009	38.39 백만 EUR	4.73 백만 EUR	1.35 백만 EUR
2010	40.4 백만 EUR	4.46 백만 EUR	2.55 백만 EUR
2011	41.85 백만 EUR	2.94 백만 EUR	2.32 백만 EUR
2012	36.84 백만 EUR	-1.27 백만 EUR	-17.1 백만 EUR
2013	29.81 백만 EUR	368,000 EUR	-3.51 백만 EUR
2014	27.61 백만 EUR	-3.45 백만 EUR	-5.01 백만 EUR
2015	27.52 백만 EUR	-7.55 백만 EUR	-7.06 백만 EUR
2016	26.25 백만 EUR	-5.46 백만 EUR	-8.41 백만 EUR
2017	16.55 백만 EUR	-7.29 백만 EUR	-12.72 백만 EUR

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
6	8	10	17	29	38	40	41	36	29	27	27	26	16
-	33.33	25.00	70.00	70.59	31.03	5.26	2.50	-12.20	-19.44	-6.90	-	-3.70	-38.46
66.67	62.50	60.00	64.71	68.97	71.05	67.50	65.85	63.89	65.52	62.96	51.85	53.85	62.50
4	5	6	11	20	27	27	27	23	19	17	14	14	10
0	2	2	3	2	1	2	2	-17	-3	-5	-7	-8	-12
-	-	-	50.00	-33.33	-50.00	100.00	-	-950.00	-82.35	66.67	40.00	14.29	50.00
9.64	9.64	9.64	7.53	9.39	9.24	9.27	9.3	9.34	9.26	9.73	10.03	10.36	13.7
-	-	-	-	-	-	-	-	-	-	-	-	-	-

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017

1.06	1.87	3.19	39.47	4.7	7.49	5.96	7.02	10.11	8.56	2.1	1.45	0.91	0.69
1.26	3.11	5.85	6.56	7.81	8.41	8.1	7.21	6.62	7.15	8.59	11.64	8.19	7.13
0.03	0	0.35	1.2	1.42	1	3.34	3.15	2.73	1.79	2.92	0.09	0.09	0.12
0.01	0.04	0.05	0.17	0.29	0.25	0.73	1.01	1.48	0.52	0.44	0.41	0.35	0.26
200	770	0	750	130	180	280	440	511	674	240	0	0	0
2.56	5.79	9.44	48.15	14.35	17.33	18.41	18.83	21.44	18.68	14.29	13.59	9.54	8.2
0.25	0.27	0.48	1.13	10.42	13.96	14.76	14.52	10.17	8.64	10.38	10.55	9.55	6.74
0	0	0	0	0	0	0	0	0	29	58	79	0	165
0.12	0.32	0.33	0.53	1.3	1.05	0.99	0.94	1.22	0.75	1.29	1.5	1.42	1.96
0	0	0	0.19	11.49	10.39	9.18	9.2	7.72	6.24	5.5	21.02	19.7	14.87
0	0	0	1.75	25.95	24.97	26.61	28.38	14.45	16.51	14.69	0	0	0
0	0	0	0.17	0.64	1.12	0.62	0.54	0.62	0.39	0.58	1.4	2.26	1.94
0.37	0.59	0.81	3.77	49.8	51.49	52.16	53.58	34.18	32.57	32.5	34.55	32.94	25.68
2.93	6.38	10.25	51.92	64.15	68.82	70.57	72.41	55.62	51.25	46.79	48.14	42.48	33.88

0.71	0.71	0.71	0.96	0.96	0.96	0.96	0.97	0.97	0.97	0.97	1.02	1.04	1.92
3.59	3.59	3.59	38.18	38.18	38.18	38.18	38.17	38.17	38.17	38.36	39.6	39.88	46.13
-4.08	-1.72	0.32	4.23	7.09	8.34	9.68	11.59	-5.85	-11.2	-16.33	-23.34	-32.02	-44.74
0	0	0	-0.02	-0.45	-0.68	-0.45	-1.56	-1.41	-1.45	-1.91	-1.97	-1.96	-1.91
50	0	0	0	770	670	570	470	374	274	174	75	0	0
0.27	2.58	4.62	43.35	46.55	47.47	48.94	49.64	32.25	26.77	21.28	15.39	6.94	1.4
0.34	0.79	0.53	2.14	1.6	1.73	1.93	2.07	2.43	2.39	4.21	12.11	15.1	13.04
400	740	0	0	0	0	0	0	0	15	194	0	0	0
0	0.12	2.04	3.18	5.8	8.41	6.86	6.68	6.68	6.6	4.14	1.27	1.1	1.05
540	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	40	180	190	190	201	202	213	424	235	459
1.28	1.65	2.57	5.32	7.44	10.32	8.98	8.94	9.31	9.2	8.76	13.8	16.44	14.55
0	0	0	0	0.11	3.8	3.6	3.4	3.21	3	4.01	5.45	5.34	5.66
0	0	0	0	2.83	2.66	2.31	2.16	1.86	1.58	1.2	1.24	0.9	0.57
1.38	2.14	3.04	3.67	10.72	8.25	8.93	10.69	11.41	10.7	11.53	12.4	13.13	12.13
1.38	2.14	3.04	3.67	13.66	14.71	14.84	16.25	16.48	15.28	16.74	19.08	19.37	18.36
2.66	3.79	5.61	8.99	21.1	25.03	23.82	25.19	25.79	24.48	25.49	32.88	35.81	32.91
2.93	6.37	10.23	52.34	67.65	72.5	72.76	74.83	58.04	51.25	46.77	48.27	42.75	34.31

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
0	2	2	3	2	1	2	2	-17	-3	-5	-7	-8	-12
0	0	0	0	1	2	2	3	3	2	2	2	2	2
0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	-1	0	-2	0	-4	0	1	0	-2	4	5	0
0	0	0	0	0	1	2	0	14	0	1	0	0	5
0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	1,000	1,000	0	0	0	0	0	0	0
1	1	1	4	2	4	2	6	2	0	-3	0	0	-3
0	0	0	-2	-9	-4	-2	-1	-1	0	-1	-2	-1	0
0	0	0	-2,000	-33,000	-5,000	-3,000	-3,000	-1,000	1,000	-1,000	-2,000	-1,000	0
0	0	0	0	-24	0	-1	-2	0	2	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	3	0	0	0	0	0	0	0	4
0	0	0	37	-3	0	0	0	0	0	0	1	0	0
0	0	0	34	-3	3	0	-1	0	0	-1	1	0	4
-	-	-	-3.00	-	-	-	-	-	-	-1.00	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	1	36	-34	2	-1	1	0	1	-6	0	0	0
1.45	1.58	1.06	1.91	-7.37	-0.08	0.43	4.41	0.67	-0.49	-4.84	-2.52	-0.56	-4.31
0	0	0	0	0	0	0	0	0	0	0	0	0	0

Esperite 브루토마진	Esperite 이익 마진	Esperite EBIT-마진	Esperite 이익 마진
2017	65.83 %	-44.02 %	-76.86 %
2016	55.88 %	-20.81 %	-32.02 %
2015	53.6 %	-27.42 %	-25.64 %
2014	62.2 %	-12.48 %	-18.16 %
2013	64.47 %	1.23 %	-11.78 %
2012	64.67 %	-3.45 %	-46.42 %
2011	66.57 %	7.03 %	5.54 %
2010	67.55 %	11.04 %	6.31 %
2009	70.9 %	12.32 %	3.52 %
2008	68.53 %	7.83 %	8.71 %
2007	64.09 %	28.63 %	21.91 %
2006	63.83 %	25.37 %	18.68 %
2005	58.36 %	29.53 %	27.1 %
2004	64.62 %	-4.09 %	-5.82 %

	브루토마진	EBIT-마진	이익 마진
2004	64.62 %	-4.09 %	-5.82 %
2005	58.36 %	29.53 %	27.1 %
2006	63.83 %	25.37 %	18.68 %
2007	64.09 %	28.63 %	21.91 %
2008	68.53 %	7.83 %	8.71 %
2009	70.9 %	12.32 %	3.52 %
2010	67.55 %	11.04 %	6.31 %
2011	66.57 %	7.03 %	5.54 %
2012	64.67 %	-3.45 %	-46.42 %
2013	64.47 %	1.23 %	-11.78 %
2014	62.2 %	-12.48 %	-18.16 %
2015	53.6 %	-27.42 %	-25.64 %
2016	55.88 %	-20.81 %	-32.02 %
2017	65.83 %	-44.02 %	-76.86 %

날짜	Esperite 주당 매출	Esperite EBIT 당 주식	Esperite 주당 이익
2017	1.21 undefined	-0.53 undefined	-0.93 undefined
2016	2.53 undefined	-0.53 undefined	-0.81 undefined
2015	2.74 undefined	-0.75 undefined	-0.7 undefined
2014	2.84 undefined	-0.35 undefined	-0.52 undefined
2013	3.22 undefined	0.04 undefined	-0.38 undefined
2012	3.94 undefined	-0.14 undefined	-1.83 undefined
2011	4.5 undefined	0.32 undefined	0.25 undefined
2010	4.36 undefined	0.48 undefined	0.28 undefined
2009	4.15 undefined	0.51 undefined	0.15 undefined
2008	3.14 undefined	0.25 undefined	0.27 undefined
2007	2.35 undefined	0.67 undefined	0.52 undefined
2006	1.13 undefined	0.29 undefined	0.21 undefined
2005	0.9 undefined	0.27 undefined	0.24 undefined
2004	0.66 undefined	-0.03 undefined	-0.04 undefined

	주당 매출	EBIT 당 주식	주당 이익
2004	0.66 EUR	-0.03 EUR	-0.04 EUR
2005	0.9 EUR	0.27 EUR	0.24 EUR
2006	1.13 EUR	0.29 EUR	0.21 EUR
2007	2.35 EUR	0.67 EUR	0.52 EUR
2008	3.14 EUR	0.25 EUR	0.27 EUR
2009	4.15 EUR	0.51 EUR	0.15 EUR
2010	4.36 EUR	0.48 EUR	0.28 EUR
2011	4.5 EUR	0.32 EUR	0.25 EUR
2012	3.94 EUR	-0.14 EUR	-1.83 EUR
2013	3.22 EUR	0.04 EUR	-0.38 EUR
2014	2.84 EUR	-0.35 EUR	-0.52 EUR
2015	2.74 EUR	-0.75 EUR	-0.7 EUR
2016	2.53 EUR	-0.53 EUR	-0.81 EUR
2017	1.21 EUR	-0.53 EUR	-0.93 EUR

	주식 수량
2004	9.64 백만 Aktien
2005	9.64 백만 Aktien
2006	9.64 백만 Aktien
2007	7.53 백만 Aktien
2008	9.39 백만 Aktien
2009	9.24 백만 Aktien
2010	9.27 백만 Aktien
2011	9.3 백만 Aktien
2012	9.34 백만 Aktien
2013	9.26 백만 Aktien
2014	9.73 백만 Aktien
2015	10.03 백만 Aktien
2016	10.36 백만 Aktien
2017	13.7 백만 Aktien

날짜	Esperite 배당률
2017	25.2 %
2016	25.08 %
2015	25.81 %
2014	24.71 %
2013	24.71 %
2012	-4.37 %
2011	28 %
2010	21.43 %
2009	24.71 %
2008	24.71 %
2007	24.71 %
2006	24.71 %
2005	24.71 %
2004	24.71 %

	배당률
2004	24.71 %
2005	24.71 %
2006	24.71 %
2007	24.71 %
2008	24.71 %
2009	24.71 %
2010	21.43 %
2011	28 %
2012	-4.37 %
2013	24.71 %
2014	24.71 %
2015	25.81 %
2016	25.08 %
2017	25.2 %

%-지분	이름	주식	변경	날짜
2.99118 %	Citadel Advisors LLC	1,565,286	371,403

What values and corporate philosophy does Esperite represent?

Esperite NV represents values of innovation, scientific excellence, and commitment to improving healthcare solutions. With a strong corporate philosophy centered around pioneering stem cell technologies, Esperite NV is dedicated to unlocking the therapeutic potential of stem cells for regenerative medicine. By leveraging its extensive expertise in cryopreservation and biomedical services, the company aims to empower patients and healthcare professionals with state-of-the-art tools for personalized medicine. Esperite NV's commitment to quality, safety, and ethical practices resonates throughout its operations, ensuring the utmost integrity in delivering advanced healthcare solutions.

In which countries and regions is Esperite primarily present?

Esperite NV, a renowned company in the stock market, primarily operates in various countries and regions. It has a significant presence in the European market, with a focus on countries such as the Netherlands, Spain, Belgium, and the United Kingdom. Additionally, Esperite NV extends its reach to key regions including the Middle East and North Africa. With its diversified portfolio and strategic partnerships, Esperite NV has established a strong foothold in these regions, allowing it to cater to a wide range of investors and stakeholders.

What significant milestones has the company Esperite achieved?

Esperite NV, a renowned company in the stock market, has achieved several significant milestones. Over the years, Esperite NV has successfully expanded its global presence, establishing a strong foothold in the field of cell therapy and biobanking. With strategic partnerships and collaborations with industry leaders, Esperite NV has propelled innovation and advancements in stem cell research. Additionally, the company has consistently delivered breakthrough technologies, contributing to the development of groundbreaking medical solutions. Esperite NV's commitment to excellence and dedication to its stakeholders have led to consistent growth and enhanced shareholder value, making it a leading player in the stock market.

What is the history and background of the company Esperite?

Esperite NV is a company with a rich history and background. Established in 2000, Esperite NV, formerly known as Cryo-Save Group NV, is a leading biotech company specializing in the collection, processing, and storage of stem cells obtained from umbilical cord blood and tissue. The company has an extensive global presence, operating multiple cryopreservation and processing laboratories across Europe and South Africa. Through its subsidiary, Cryo-Save, Esperite NV has successfully stored over 325,000 samples, providing families with a valuable resource for future medical treatments. With a strong commitment to research and innovation, Esperite NV continues to contribute significantly to the advancement of regenerative medicine and stem cell-based therapies.

Who are the main competitors of Esperite in the market?

Esperite NV faces competition from several companies in the market. Some of its main competitors include Cryo-Save Group, StemCare, and FamilyCord. These companies also operate in the field of stem cell banking and offer similar services. However, Esperite NV distinguishes itself through its innovative technology and extensive global presence. It strives to maintain a competitive edge by continuously advancing its product offerings and expanding its customer base.

In which industries is Esperite primarily active?

Esperite NV is primarily active in the healthcare industry.

What is the business model of Esperite?

The business model of Esperite NV focuses on offering innovative solutions in the field of biotechnology, particularly in the area of stem cells. Esperite NV, a company based in the Netherlands, is dedicated to the development and commercialization of advanced therapies for regenerative medicine, cellular therapy, and personalized medicine. This includes the collection, processing, storage, and distribution of stem cells from multiple sources, such as umbilical cord blood and tissue. By leveraging their expertise and partnerships, Esperite NV aims to provide valuable medical services and products that contribute to improving patient outcomes and healthcare advancements.

Esperite 2024의 P/E 비율은 얼마입니까?

Esperite에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

Esperite 2024의 KUV는 얼마입니까?

Esperite에 대한 현재 KUV는 계산할 수 없습니다.

Esperite의 AlleAktien 품질 점수는 얼마인가요?

Esperite에 대한 AlleAktien 품질 점수는 3/10입니다.

Esperite 2024의 매출은 얼마인가요?

Esperite에 대한 현재 매출은 계산할 수 없습니다.

Esperite 2024의 이익은 얼마인가요?

Esperite의 현재 이익을 계산할 수 없습니다.

Esperite은 무엇을 하나요?

Esperite NV is a Dutch company specializing in life sciences. It operates a diversified business model consisting of various divisions to achieve its goals in research and development and the provision of services to the medical industry. The company's primary division is the biological cell banking unit, operating under the brand name CryoSave. CryoSave collects stem cells from umbilical cord blood and tissue, dental pulp, milk teeth, adipose tissue, and other tissues with high healing potential. These stem cells are used in the treatment of diseases such as diabetes, cancer, neurological disorders, and other serious conditions. The company also operates the Progenity AB division, a biotech company specializing in the development and production of solutions for cell transfection and culture. Progenity AB also provides services for in vitro research, such as cell line development, cell culture provision, and management. Esperite NV also operates the DNA amplification division, operating under the brand name LifeCode. LifeCode is a leading provider of DNA amplification solutions for the forensic, medical, and scientific community. LifeCode's solutions include reagents and instruments for polymerase chain reaction (PCR) and other amplification and sequencing technologies. Additionally, the company is also involved in the field of animal health, particularly in cattle breeding. Esperite NV's animal health division operates under the name Cryo-Save Agro, providing leading services in cattle semen and genetic advisory services to breeders. In addition to its businesses in biological research and development, Esperite NV is also involved in clinical trials. The company provides services for the planning of clinical trials, development of protocols, and data management for studies. Esperite NV also operates a charity organization, the Cord for Life Foundation, which functions as a nonprofit organization collecting funds for charitable purposes to support stem cell research and development and promote public awareness of the benefits of stem cell therapies. In summary, Esperite NV operates a diverse business model focusing on the research and development of biological solutions and services. With its divisions in biological cell banking, cell transfection and culture, DNA amplification, animal health, and clinical trials, the company offers a wide range of products and services to its customers, contributing to the advancement of science in the field of regenerative medicine and driving progress in the medical industry.

Esperite 배당금은 얼마입니까?

Esperite은(는) 연간 번의 배당을 통해 0 EUR의 배당금을 지급합니다.

Esperite이 얼마나 자주 배당을 지급하나요?

Esperite의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Esperite ISIN이 무엇입니까?

Esperite의 ISIN은 NL0009272137입니다.

Esperite 티커는 무엇인가요?

Esperite의 티커는 ESP.AS입니다.

Esperite이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Esperite은(는) 0.08 EUR 의 배당금을 지급했습니다. 이는 약 869.57 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Esperite은(는) 0 EUR의 배당금을 지급할 것으로 예상됩니다.

Esperite의 배당 수익률은 얼마입니까?

Esperite의 현재 배당 수익률은 869.57 %입니다.

Esperite의 배당금은 언제 지급되나요?

Esperite은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Esperite의 배당금은 얼마나 안전한가요?

Esperite은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Esperite의 배당금은 얼마입니까?

향후 12개월 동안 0 EUR의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Esperite이(가) 속해 있는 섹터는 어디인가요?

Esperite은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Esperite kaufen, um die vorherige Dividende zu erhalten?

Esperite의 마지막 배당금을 0.08 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Esperite의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Esperite의 2023년도 배당금은 얼마였습니까?

2023년에 Esperite는 0 EUR를 배당금으로 지급했습니다.

Esperite는 어떤 화폐로 배당금을 지급하나요?

Esperite의 배당금은 EUR에 지급됩니다.

증권거래소	Esperite 티커
AMSTERDAM	ESP.AS
EURONEXT	ESP.AS
LONDON	0OMG.L

Esperite 티커	Esperite FIGI
CRYVF:UV	BBG000VHK193
CRYOUSD:XS	BBG0015GYKX8
CRYOEUR:XS	BBG002K0N514
CRYOEUR:EU	BBG0058LZZF1
ESP:FP	BBG006RZ8HH5
ESPA:B3	BBG006TPG4H5
ESPA:L3	BBG006TPNBC6
ESPA:PO	BBG008GZM9T2
ESPA:L1	BBG00Y90YC29

한 눈에 저평가된 주식을 인식하세요

Esperite 주식 주식과 주식 분석 Esperite ariva, Esperite onvista, Esperite finanzen.net, Esperite aktienfinder, Esperite marketscreener, Esperite marketwatch, Esperite bloomberg, Esperite handelsblatt, Esperite wiwo, Esperite forum

가격

가격

티커ESP.AS

ISINNL0009272137

Esperite 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Esperite 주가 이력

Esperite 주식 매출, EBIT, 이익 NL0009272137 ·

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Esperite 매출, 이익 및 EBIT 역사

Esperite 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Esperite 주식 마진 NL0009272137 ·

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Esperite 마진 역사

Esperite 주식 매출, EBIT, 주당 순이익 NL0009272137 ·

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Esperite 매출, 이익 및 EBIT 주당 역사

Esperite 주식 및 주식 분석

한눈에 과소평가된 주식을 인식하세요.

Esperite Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Esperite 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

Esperite 주식 수량 NL0009272137 ·

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Esperite 주식 배당률 NL0009272137 ·

배당비율

연간 배당비율이란 무엇인가요?

데이터 해석 방법

투자에 대한 데이터 사용

Esperite 배당금지급률 역사

한눈에 과소평가된 주식을 인식하세요.

Esperite 수익 예상

Esperite 수익 놀라움

Esperite 주식 주주 구조

Esperite 임원진 및 경영진

Esperite 주식
주식과 주식 분석 Esperite ariva, Esperite onvista, Esperite finanzen.net, Esperite aktienfinder, Esperite marketscreener, Esperite marketwatch, Esperite bloomberg, Esperite handelsblatt, Esperite wiwo, Esperite forum

티커
ESP.AS

ISIN
NL0009272137